kh631
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 6, 2023 (NCT05672121)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AImmunity, passive
VEGFA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05657301 | Phase 1 | Apr 30, 2023 | Government of China |
| NCT05672121 | Phase 1/Phase 2 (Phase 2) | Feb 6, 2023 | Capital Medical University, Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2023 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1